Jagsonpal Pharma Q4 FY26: Revenue up 10%, PAT up 31%; ₹40 Cr Buyback Approved, 200% Dividend Proposed
Jagsonpal Pharmaceuticals reported Q4 FY26 revenue up 10% to ₹64.2 crore and PAT up 31% to ₹8.8 crore. For FY26, revenue grew 7% to ₹287.2 crore, and PAT rose 19% to ₹44.6 crore. The company proposed a 200% dividend and approved a ₹40 crore share buyback at ₹250 per share.
The announcement includes significant financial performance improvements and substantial shareholder return initiatives like a proposed buyback and increased dividend, which are likely to have a high impact on investor sentiment and the company's stock.
The company reported strong year-on-year growth in revenue and profit for both the quarter and the full fiscal year. The proposed dividend increase and share buyback indicate a positive outlook and a commitment to shareholder value.
Jagsonpal Pharmaceuticals Limited announced its audited financial results for the quarter and year ended March 31, 2026. For the fourth quarter of FY26, the company reported a revenue of ₹64.2 crore (₹642 Mn), a 9.6% increase year-on-year, and a Profit After Tax (PAT) of ₹8.8 crore (₹88 Mn), up 31% YoY. The company's operating EBITDA stood at ₹10.6 crore (₹106 Mn) for the quarter.
For the full fiscal year FY26, revenue grew by 6.9% to ₹287.2 crore (₹2,872 Mn), with operating EBITDA at ₹60.9 crore (₹609 Mn). PAT for FY26 increased by 19% to ₹44.6 crore (₹446 Mn). The company ended the fiscal year with a robust cash position of ₹191 crore (₹1,907 Mn).
In a significant move for shareholder value, the Board has recommended a higher dividend distribution of 200% (including a 75% special dividend), amounting to approximately ₹26.2 crore (₹262 Mn). Furthermore, the company announced a proposed buyback of up to 16 lakh equity shares at ₹250 per share, with a total outlay of ₹40 crore. Promoters will not participate in this buyback. This strategic capital allocation is expected to improve ROCE from 22.0% to 25.7% and ROE from 16.2% to 18.9%.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.